These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 8280612

  • 1. Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools.
    Hoyes KP, Porter JB.
    Br J Haematol; 1993 Oct; 85(2):393-400. PubMed ID: 8280612
    [Abstract] [Full Text] [Related]

  • 2. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell.
    Richardson D, Ponka P, Baker E.
    Cancer Res; 1994 Feb 01; 54(3):685-9. PubMed ID: 8306330
    [Abstract] [Full Text] [Related]

  • 3. In vivo and in vitro effects of 3-hydroxypyridin-4-one chelators on murine hemopoiesis.
    Hoyes KP, Jones HM, Abeysinghe RD, Hider RC, Porter JB.
    Exp Hematol; 1993 Jan 01; 21(1):86-92. PubMed ID: 8417963
    [Abstract] [Full Text] [Related]

  • 4. Studies of in vivo iron mobilization by chelators in the ferrocene-loaded rat.
    Florence A, Ward RJ, Peters TJ, Crichton RR.
    Biochem Pharmacol; 1992 Sep 25; 44(6):1023-7. PubMed ID: 1417929
    [Abstract] [Full Text] [Related]

  • 5. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect.
    Boelaert JR, Van Cutsem J, de Locht M, Schneider YJ, Crichton RR.
    Kidney Int; 1994 Mar 25; 45(3):667-71. PubMed ID: 8196268
    [Abstract] [Full Text] [Related]

  • 6. Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell lines.
    Hoyes KP, Hider RC, Porter JB.
    Cancer Res; 1992 Sep 01; 52(17):4591-9. PubMed ID: 1511427
    [Abstract] [Full Text] [Related]

  • 7. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.
    Devanur LD, Evans RW, Evans PJ, Hider RC.
    Biochem J; 2008 Jan 15; 409(2):439-47. PubMed ID: 17919118
    [Abstract] [Full Text] [Related]

  • 8. Effect of desferrioxamine, rhodotorulic acid and cholylhydroxamic acid on transferrin and iron exchange with hepatocytes in culture.
    Baker E, Page M, Torrance J, Grady R.
    Clin Physiol Biochem; 1985 Jan 15; 3(6):277-88. PubMed ID: 4075694
    [Abstract] [Full Text] [Related]

  • 9. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use.
    Porter JB, Rafique R, Srichairatanakool S, Davis BA, Shah FT, Hair T, Evans P.
    Ann N Y Acad Sci; 2005 Jan 15; 1054():155-68. PubMed ID: 16339661
    [Abstract] [Full Text] [Related]

  • 10. Direct comparison of delta-aminolevulinic acid and methyl-aminolevulinate-derived protoporphyrin IX accumulations potentiated by desferrioxamine or the novel hydroxypyridinone iron chelator CP94 in cultured human cells.
    Pye A, Curnow A.
    Photochem Photobiol; 2007 Jan 15; 83(3):766-73. PubMed ID: 17576385
    [Abstract] [Full Text] [Related]

  • 11. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone.
    Richardson DR, Milnes K.
    Blood; 1997 Apr 15; 89(8):3025-38. PubMed ID: 9108424
    [Abstract] [Full Text] [Related]

  • 12. Chelation of transferrin iron by desferrioxamine in K562 cells. The partition of iron between ferrioxamine and ferritin.
    Roberts S, Bomford A.
    Biochem J; 1988 Sep 15; 254(3):869-75. PubMed ID: 3196300
    [Abstract] [Full Text] [Related]

  • 13. Cellular uptake and release of two contrasting iron chelators.
    Cable H, Lloyd JB.
    J Pharm Pharmacol; 1999 Feb 15; 51(2):131-4. PubMed ID: 10217310
    [Abstract] [Full Text] [Related]

  • 14. Cellular zinc content is a major determinant of iron chelator-induced apoptosis of thymocytes.
    Maclean KH, Cleveland JL, Porter JB.
    Blood; 2001 Dec 15; 98(13):3831-9. PubMed ID: 11739193
    [Abstract] [Full Text] [Related]

  • 15. The transport of two iron chelators, desferrioxamine B and L1, across Caco-2 monolayers.
    Hamilton KO, Stallibrass L, Hassan I, Jin Y, Halleux C, Mackay M.
    Br J Haematol; 1994 Apr 15; 86(4):851-7. PubMed ID: 7918082
    [Abstract] [Full Text] [Related]

  • 16. Desferrithiocin and desferrioxamine B. Cellular pharmacology and storage iron mobilization.
    Jin Y, Baquet A, Florence A, Crichton RR, Schneider YJ.
    Biochem Pharmacol; 1989 Oct 01; 38(19):3233-40. PubMed ID: 2818622
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of iron toxicity in rat and human hepatocyte cultures by the hydroxypyridin-4-ones CP20 and CP94.
    Chenoufi N, Hubert N, Loréal O, Morel I, Pasdeloup N, Cillard J, Brissot P, Lescoat G.
    J Hepatol; 1995 Aug 01; 23(2):166-73. PubMed ID: 7499788
    [Abstract] [Full Text] [Related]

  • 18. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents.
    Richardson DR, Tran EH, Ponka P.
    Blood; 1995 Dec 01; 86(11):4295-306. PubMed ID: 7492790
    [Abstract] [Full Text] [Related]

  • 19. Contrasting interspecies efficacy and toxicology of 1,2-diethyl-3-hydroxypyridin-4-one, CP94, relates to differing metabolism of the iron chelating site.
    Porter JB, Abeysinghe RD, Hoyes KP, Barra C, Huehns ER, Brooks PN, Blackwell MP, Araneta M, Brittenham G, Singh S.
    Br J Haematol; 1993 Sep 01; 85(1):159-68. PubMed ID: 8251385
    [Abstract] [Full Text] [Related]

  • 20. Structure-function investigation of the interaction of 1- and 2-substituted 3-hydroxypyridin-4-ones with 5-lipoxygenase and ribonucleotide reductase.
    Kayyali R, Porter JB, Liu ZD, Davies NA, Nugent JH, Cooper CE, Hider RC.
    J Biol Chem; 2001 Dec 28; 276(52):48814-22. PubMed ID: 11602611
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.